arrow
B

Barbara De Moerloose

ghent university hospital
H指数:48
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
Leukemia
IF13.4
2026-08-310
OA
Sinusoidal obstruction syndrome in children with B‐acute lymphoblastic leukemia (B‐ALL) treated with inotuzumab ozogamicin: Results from the ITCC‐059 trial

窦性阻塞综合征在用伊诺妥单抗奥佐米星治疗B-急性淋巴细胞白血病(B-ALL)的儿童中的发生情况:ITCC-059试验结果

2026-08-210
OAAI
Characteristics and Outcomes of Adolescents (15–18 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML

慢性粒细胞白血病慢性期青少年(15–18岁)的特征与结局:国际儿童CML登记研究的经验

Cancers
IF4.4
2026-06-170
OA
Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial

奥佐米星-伊诺他珠单抗在儿科极高危首次B细胞急性淋巴细胞白血病复发中的应用(ITCC-059):一项多中心、单臂、II期临床试验

2026-06-150
PRE
Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia

分析组蛋白翻译后修饰以识别T细胞急性淋巴细胞白血病中表观遗传药物反应的特征。

2026-03-260
OAAI
ADVANCED DRUG RESPONSE PROFILING AND IMMUNOPHENOTYPING TO PRIORITIZE TREATMENT OPTIONS FOR PEDIATRIC MDS WITH EXCESS BLASTS
2025-11-010
OAAI
GENETIC LANDSCAPE AND OUTCOMES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH THERAPY-RELATED MYELOID NEOPLASMS

治疗相关性髓系肿瘤儿童和青少年造血干细胞移植后的遗传景观和结局

2025-11-010
OA
IMPROVED ENGRAFTMENT FOLLOWING A TREOSULFAN-FLUDARABINE CONDITIONING REGIMEN COMPARED TO THIOTEPA-FLUDARABINE IN PATIENTS WITH REFRACTORY CYTOPENIA OF CHILDHOOD

与噻替帕-氟达拉滨相比,TREOSULFAN-氟达拉滨预处理方案改善了儿童难治性血细胞减少症患者的植入

2025-11-010
OAAI
OUTCOMES OF RABBIT VS. HORSE ANTI-THYMOCYTE GLOBULIN IN IMMUNOSUPPRESSIVE THERAPY FOR REFRACTORY CYTOPENIA OF CHILDHOOD
2025-11-010
OAAI
LONG-TERM OUTCOME OF AN OBSERVATIONAL APPROACH IN PATIENTS WITH NRAS-MUTATED JUVENILE MYELOMONOCYTIC LEUKEMIA AND ABSENCE OF HIGH RISK FEATURES
2025-11-010
OA
INTEGRATED IMMUNOPHENOTYPING AND DRUG RESPONSE PROFILING REVEALS SUBTYPE-SPECIFIC SUSCEPTIBILITIES IN PEDIATRIC MDS WITH EXCESS BLASTS
2025-11-010
OA
CPX-351 in Down Syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase III ML-DS 2018 Trial

CPX-351在Down Syndrome-associated Myeloid Leukemia中的研究结果及预后因素:来自III期ML-DS 2018试验的数据

Blood
IF23.1
2025-10-240
OAAI
Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

儿童急性髓系白血病(AML)的诊断与管理:国际专家小组的共识建议

Blood
IF23.1
2025-10-220
PRE
Characteristics and prognosis of paediatric normal karyotype acute myeloid leukaemia: A NOPHO-DBH AML study

儿童正常核型急性髓系白血病的特点与预后:NOPHO-DBH AML研究

2025-08-180
OA
Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency

年龄依赖性的表型和分子进化:源于GATA2缺乏的儿科MDS

2025-07-150
OAAI
Exploring germline variants in genes associated with inborn errors of immunity and inherited bone marrow failure syndromes in pediatric hematological malignancies

探索与免疫性先天性错误和遗传性骨髓衰竭综合征相关的基因在儿童血液恶性肿瘤中的生殖系变异。

2025-07-050
PRE
Results of the prospective EORTC Children Leukemia Group study 58081 in precursor B- and T-cell acute lymphoblastic leukemia
2024-11-130
OAAI